%0 Journal Article
%T TGF-¦Â Signaling Cooperates with AT Motif-Binding Factor-1 for Repression of the ¦Á-Fetoprotein Promoter
%A Nobuo Sakata
%A Satoshi Kaneko
%A Souichi Ikeno
%A Yutaka Miura
%A Hidekazu Nakabayashi
%A Xue-Yuan Dong
%A Jin-Tang Dong
%A Taiki Tamaoki
%A Naoko Nakano
%A Susumu Itoh
%J Journal of Signal Transduction
%D 2014
%I Hindawi Publishing Corporation
%R 10.1155/2014/970346
%X ¦Á-Fetoprotein (AFP) is known to be highly produced in fetal liver despite its barely detectable level in normal adult liver. On the other hand, hepatocellular carcinoma often shows high expression of AFP. Thus, AFP seems to be an oncogenic marker. In our present study, we investigated how TGF-¦Â signaling cooperates with AT motif-binding factor-1 (ATBF1) to inhibit AFP transcription. Indeed, the expression of AFP mRNA in HuH-7 cells was negatively regulated by TGF-¦Â signaling. To further understand how TGF-¦Â suppresses the transcription of the AFP gene, we analyzed the activity of the AFP promoter in the presence of TGF-¦Â. We found that the TGF-¦Â signaling and ATBF1 suppressed AFP transcription through two ATBF1 binding elements (AT-motifs). Using a heterologous reporter system, both AT-motifs were required for transcriptional repression upon TGF-¦Â stimulation. Furthermore, Smads were found to interact with ATBF1 at both its N-terminal and C-terminal regions. Since the N-terminal (ATBF1N) and C-terminal regions of ATBF1 (ATBF1C) lack the ability of DNA binding, both truncated mutants rescued the cooperative inhibitory action by the TGF-¦Â signaling and ATBF1 in a dose-dependent manner. Taken together, these findings indicate that TGF-¦Â signaling can act in concert with ATBF1 to suppress the activity of the AFP promoter through direct interaction of ATBF1 with Smads. 1. Introduction The oncofetal glycoprotein ¦Á-fetoprotein (AFP) is a major serum protein expressed at high levels in the yolk sac and liver during embryonic development [1, 2]. However, AFP in adult serum is undetectable except in patients who suffer from hepatocellular carcinoma (HCC). Thus, AFP is a useful tumor marker for measuring the malignancy grade of HCC [3]. The human AFP gene is activated by hepatocyte nuclear factor-1 (HNF-1), which can bind to an AT-motif in the proximal and/or distal promoter region of AFP [4¨C6]. AT motif-binding factor-1 (ATBF1) encodes a protein comprising multiple zinc fingers and homeodomains [7, 8]. ATBF1 was originally discovered as a negative transcriptional regulator of the human AFP gene, which competes with HNF-1 for binding to the AT-motifs [4]. Thus, ATBF1 seems to act as a transcriptional repressor of the AFP gene [4, 9, 10]. Besides the AFP gene, ATBF1 can also negatively regulate the transcription of the Myb gene [11]. When ATBF1 was overexpressed in C2C12 cells, the expression of Id3 and cyclin D increased, whereas that of MyoD and myogenin did not [12]. Thus, ATBF1 seems to play a key role not only as a negative, but also as a positive
%U http://www.hindawi.com/journals/jst/2014/970346/